PAVM

PAVmed Inc. Common Stock (PAVM)

Stock · NASDAQ · Health Care

$2.39as of 10/16/2026

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 2, 2026

PAVmed Included in List of Moving Health Care Stocks. PAVmed was featured in a Benzinga article highlighting health care stocks with notable intraday movement on Thursday. The stock is currently trading near its 52-week low, with technical indicators showing oversold conditions and a recent breakdown below support levels. This inclusion reflects current market attention to the stock's price action rather than a specific corporate announcement.

Active signals

Resistance level
$5.03
Industry
Medical/Dental Instruments

What PAVM's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.

SignalTimesMedian 20-session returnHigher after 20 sessions
Bollinger Band Breakdown21-2.4%38%
Bollinger Band Breakout15-22.2%20%
Volume Spike10-15.9%30%
Any 20-session window (baseline)-7.6%32%

Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.

About PAVM

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing…

Sector
Health Care
Industry
Medical/Dental Instruments
Employees
41

Fundamentals

1-day range
$2.43$2.5
Market cap
$35.93M
P/E (trailing)
—
P/E (forward)
-1.05
EPS (trailing)
$-9.80
Dividend yield
—
Beta
0.86
Avg. volume
29.7K
52-week range
$2.27$28.44
Next earnings: November 12, 2026 · EPS estimate $-0.66confirmed

How PAVmed Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$71.0KNet Income$401.0K (565%)SG&A$17.17M (24179%)R&D$4.49M (6327%)Cost of Revenue$218.0K (307%)PAVM

Source: 10-K filed Mar 27, 2026 · via SEC EDGAR / Finnhub

Gross Profit-$147.0K(-207%)
Operating Income-$21.81M(-30713%)

Forecasts

2 analyst ratings

Buy 88%
Hold 13%
Sell 0%
1-year price forecast
High
$57
+2284.9%
Median
$36.5
+1427.2%
Low
$16
+569.5%

PAVmed Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • PAVM
    PAVmed Inc. Common Stock
    $2.41
    ▼ 0.62%
    Market cap $35.93MP/E —
    $2.27$28.44
  • NSPR
    InspireMD Inc. Common Stock
    $0.46
    ▼ 4.17%
    Market cap $33.87MP/E —
    $0.4604$2.54
  • ARAY
    Accuray Incorporated Common Stock
    $0.16
    ▼ 5.88%
    Market cap $33.63MP/E —
    $0.1615$1.86
  • TELA
    TELA Bio Inc. Common Stock
    $0.975
    ▼ 3.47%
    Market cap $38.50MP/E —
    $0.5011$1.56
  • NEPH
    Nephros Inc. Common Stock
    $3.65
    ▲ 3.99%
    Market cap $38.98MP/E 21.52
    $2.66$6.42
  • BEAT
    Heartbeam Inc. Common Stock
    $0.436
    ▲ 0.93%
    Market cap $28.33MP/E —
    $0.355$4
  • CNSY
    Cerenome Inc. Common Stock
    $1.7
    ▼ 9.57%
    Market cap $26.57MP/E —
    $1.49$4.16

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

Institutional Ownership

March 31, 2026

Total shares held
506.6K
Total value held
$5.14M
Institutional holders
18
Top holders this quarter
  • Unknown461.5K
  • Unknown23.8K
  • Unknown11.8K
  • Unknown5.9K
  • Unknown2.4K
  • Unknown622
  • Unknown165
  • Unknown157
  • Unknown75
  • Unknown67

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.